UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 For the transition period from to Commission file number 001-14895 SAREPTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (I.R.S. Employer Identification No.) Regi ...

| --- | --- | --- | --- | |-----------------------------------------------------------------|-------|--------------------------------------------------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | SRP-9001: New Clinical Data and Integrated Analysis | | | | | | | | | | DOUG INGRAM President and Chief Executive Officer | | | | | LOUISE RODINO-KLAPAC, PH.D. | | | | | Executive Vice President, Head of R&D, Chief Scientific Officer | | | | | July 6, 2022 8:30 a.m. ET | | | | | | | ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Mary Jenkins - Senior Manager of Investor Relations Dallan Murray - Senior Vice President & Chief Customer Officer Doug Ingram - President & Chief Executive Officer Ian Estepan - Executive Vice President & Chief Financial Officer Louise Rodino-Klapac - Executive Vice President, Chief Scientific Officer and Head of R&D Conference Call Participants Colin Bristow - UBS Brian Abrahams - RBC Capi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 93-0797222 (State or other juri ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q4 2021 Earnings Conference Call March 1, 2022 4:30 PM ET Company Participants Mary Jenkins - Senior Manager of Investor Relations Doug Ingram - President & Chief Executive Officer Ian Estepan - Executive Vice President & Chief Financial Officer Dallan Murray - Senior Vice President & Chief Commercial Officer Gilmore O'Neill - Executive Vice President of R&D & Chief Medical Officer Louise Rodino-Klapac - Executive Vice President & Chief Scientific Officer Conference ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number : 001-14895 Sarepta Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 93-0797222 (State or other jurisdi ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q3 2021 Earnings Conference Call November 3, 2021 4:30 PM ET Company Participants Mary Jenkins - Senior Manager of Investor Relations Doug Ingram - President & Chief Executive Officer Ian Estepan - Executive Vice President & Chief Financial Officer Dallan Murray - Senior Vice President & Chief Commercial Officer Gilmore O'Neill - Executive Vice President of R&D & Chief Medical Officer Louise Rodino-Klapac - Executive Vice President & Chief Scientific Officer Conferen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 93-0797222 (State or other ...

Summary of Sarepta Therapeutics, Inc. Conference Call Company Overview - **Company**: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - **Industry**: Biotechnology, specifically focusing on therapies for Duchenne muscular dystrophy (DMD) Key Highlights 1. **Progress on SRP-5051**: The company is ahead of schedule in its clinical trials, aiming to dose the first patient in Q4 2021, earlier than initially planned [2][3] 2. **MOMENTUM Trial**: The pivotal trial for accelerated approval is referred to as Part B of the MOMENTUM study, with promising initial data showing significant exon skipping and dystrophin production compared to existing therapies [4][5] 3. **Dystrophin Production**: Initial results indicated an exon skipping rate 18 times greater than eteplirsen, with a projected dystrophin level exceeding 10% after one year of treatment [4][5][16] 4. **FDA Interaction**: The company has established a positive relationship with the FDA's Neurology division, which has experience with DMD, and has received guidance on using dystrophin as a surrogate endpoint for accelerated approval [7][9] 5. **Safety Profile**: Concerns regarding hypomagnesemia have been addressed, with the company confident that it can be managed through oral supplements [18][20] 6. **PPMO Platform**: The PPMO technology has the potential to treat approximately 80% of DMD patients, with ongoing efforts to develop therapies for rare mutations [26][39] 7. **Gene Therapy Synergy**: The company is exploring the potential for synergistic effects between its PPMO platform and gene therapy, SRP-9001, to provide comprehensive treatment options for DMD [28][29] 8. **Competitive Advantage**: Sarepta claims to have unique results in human trials with its PMO and PPMO therapies, setting it apart from competitors [32][34] Additional Insights 1. **Patient Compliance**: The company reports a compliance rate of over 90% for its therapies, indicating strong patient adherence despite the challenges posed by the pandemic [13] 2. **Future Directions**: The company plans to expand its research into other neuromuscular diseases and is focused on developing additional constructs for other skip amenable mutations [39][38] 3. **Upcoming Trials**: The company is preparing for the launch of the 301 study, which will be a double-blind, placebo-controlled trial with a primary endpoint of functional output [48][50] This summary encapsulates the key points discussed during the conference call, highlighting the company's advancements, regulatory interactions, and future plans in the biotechnology sector focused on DMD.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Morgan Stanley 19th Annual Global Healthcare Conference Call September 13, 2021 1:15 PM ET Company Participants Doug Ingram - Chief Executive Officer Ian Estepan - Chief Financial Officer Conference Call Participants Matthew Harrison - Morgan Stanley Matthew Harrison Well, good afternoon everybody. Thanks for joining us for our next session. I am Matthew Harrison, one of the biopharma analysts here at Morgan Stanley. Very pleased to have Sarepta with us for the next ...